Cargando…

Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer

BACKGROUND: Small cell lung cancer (SCLC) is an aggressive malignancy. Surgical resection is currently only recommended for clinical stage I patients who have been carefully staged. The clinical outcomes of patients with resected SCLCs vary because the disease is highly heterogeneous, suggesting tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yina, Dong, Yangyang, Zhou, Yingxu, Chen, Gongyan, Hong, Xuan, Zhang, Qingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718634/
https://www.ncbi.nlm.nih.gov/pubmed/36605462
http://dx.doi.org/10.1155/2022/4183326
_version_ 1784843131257094144
author Gao, Yina
Dong, Yangyang
Zhou, Yingxu
Chen, Gongyan
Hong, Xuan
Zhang, Qingyuan
author_facet Gao, Yina
Dong, Yangyang
Zhou, Yingxu
Chen, Gongyan
Hong, Xuan
Zhang, Qingyuan
author_sort Gao, Yina
collection PubMed
description BACKGROUND: Small cell lung cancer (SCLC) is an aggressive malignancy. Surgical resection is currently only recommended for clinical stage I patients who have been carefully staged. The clinical outcomes of patients with resected SCLCs vary because the disease is highly heterogeneous, suggesting that selected patients could be considered for surgical resection depending on their clinical and/or molecular characteristics. METHODS: We collected data on a retrospective cohort of 119 limited-stage SCLC patients who underwent lobectomy with mediastinal lymph node dissection from March 2013 to March 2020 at Harbin Medical University Cancer Hospital. Correlations were derived using Fisher's exact test. Models of 2-year and 3-year survival were evaluated by deriving the area under receiver operating characteristic curves. Kaplan–Meier and Cox regression analyses were used to evaluate significant differences between the survival curves and hazard ratios. RESULTS: The median disease-free survival (DFS) was 35.9 months (range 0.9–105.3 months), and the median overall survival (OS) was 45.2 months (range 4.8–105.3 months). Univariate analysis showed that TNM stage was significantly correlated with DFS and OS. The 2-year disease-free rates of patients with stage I, II, and III disease were 76.4%, 50.5%, and 36.1%, respectively, and the 3-year OS rates were 75.9%, 57.7%, and 34.4%, respectively. In pN + patients, multiple (or multiple-station) lymph node involvement significantly increased recurrence and reduced survival compared with patients with single or single-station metastases. Patients with peripheral SCLCs evidenced significantly better DFS and OS than did patients with central tumors. Multivariate analysis showed that TNM stage and tumor location were independently prognostic in Chinese patients with resected limited-stage SCLC. A combination of TNM stage and tumor location was helpful for prognosis. CONCLUSIONS: TNM stage and tumor location were independently prognostic in Chinese patients with resected SCLCs. Patient stratification by tumor location should inform the therapeutic strategy. The role of surgical resection for limited-stage SCLC patients must be reevaluated, as this may be appropriate for some patients.
format Online
Article
Text
id pubmed-9718634
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-97186342023-01-04 Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer Gao, Yina Dong, Yangyang Zhou, Yingxu Chen, Gongyan Hong, Xuan Zhang, Qingyuan Int J Clin Pract Research Article BACKGROUND: Small cell lung cancer (SCLC) is an aggressive malignancy. Surgical resection is currently only recommended for clinical stage I patients who have been carefully staged. The clinical outcomes of patients with resected SCLCs vary because the disease is highly heterogeneous, suggesting that selected patients could be considered for surgical resection depending on their clinical and/or molecular characteristics. METHODS: We collected data on a retrospective cohort of 119 limited-stage SCLC patients who underwent lobectomy with mediastinal lymph node dissection from March 2013 to March 2020 at Harbin Medical University Cancer Hospital. Correlations were derived using Fisher's exact test. Models of 2-year and 3-year survival were evaluated by deriving the area under receiver operating characteristic curves. Kaplan–Meier and Cox regression analyses were used to evaluate significant differences between the survival curves and hazard ratios. RESULTS: The median disease-free survival (DFS) was 35.9 months (range 0.9–105.3 months), and the median overall survival (OS) was 45.2 months (range 4.8–105.3 months). Univariate analysis showed that TNM stage was significantly correlated with DFS and OS. The 2-year disease-free rates of patients with stage I, II, and III disease were 76.4%, 50.5%, and 36.1%, respectively, and the 3-year OS rates were 75.9%, 57.7%, and 34.4%, respectively. In pN + patients, multiple (or multiple-station) lymph node involvement significantly increased recurrence and reduced survival compared with patients with single or single-station metastases. Patients with peripheral SCLCs evidenced significantly better DFS and OS than did patients with central tumors. Multivariate analysis showed that TNM stage and tumor location were independently prognostic in Chinese patients with resected limited-stage SCLC. A combination of TNM stage and tumor location was helpful for prognosis. CONCLUSIONS: TNM stage and tumor location were independently prognostic in Chinese patients with resected SCLCs. Patient stratification by tumor location should inform the therapeutic strategy. The role of surgical resection for limited-stage SCLC patients must be reevaluated, as this may be appropriate for some patients. Hindawi 2022-11-25 /pmc/articles/PMC9718634/ /pubmed/36605462 http://dx.doi.org/10.1155/2022/4183326 Text en Copyright © 2022 Yina Gao et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gao, Yina
Dong, Yangyang
Zhou, Yingxu
Chen, Gongyan
Hong, Xuan
Zhang, Qingyuan
Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer
title Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer
title_full Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer
title_fullStr Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer
title_full_unstemmed Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer
title_short Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer
title_sort peripheral tumor location predicts a favorable prognosis in patients with resected small cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718634/
https://www.ncbi.nlm.nih.gov/pubmed/36605462
http://dx.doi.org/10.1155/2022/4183326
work_keys_str_mv AT gaoyina peripheraltumorlocationpredictsafavorableprognosisinpatientswithresectedsmallcelllungcancer
AT dongyangyang peripheraltumorlocationpredictsafavorableprognosisinpatientswithresectedsmallcelllungcancer
AT zhouyingxu peripheraltumorlocationpredictsafavorableprognosisinpatientswithresectedsmallcelllungcancer
AT chengongyan peripheraltumorlocationpredictsafavorableprognosisinpatientswithresectedsmallcelllungcancer
AT hongxuan peripheraltumorlocationpredictsafavorableprognosisinpatientswithresectedsmallcelllungcancer
AT zhangqingyuan peripheraltumorlocationpredictsafavorableprognosisinpatientswithresectedsmallcelllungcancer